# A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Source: https://onco.cc/trials/nct07586202/  
OnCo record `nct07586202` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Amivantamab, Lazertinib, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC is a phase 2 interventional study registered as NCT07586202 by Janssen Research & Development, LLC, with 68 participants planned, started 2026-07-28 and due to reach its primary completion in 2028-03-02. Interventions recorded: Amivantamab, Lazertinib, Carboplatin and Pemetrexed.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07586202
- Phase: 2
- Setting: A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT07586202: https://clinicaltrials.gov/study/NCT07586202

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct07586202.json